Wednesday | March 3, 2021

A large proportion of the benefit that a person gets from taking a real drug or receiving a treatment to alleviate pain is due to an individual's mindset, not to the drug itself. Understanding the neural mechanisms driving this placebo effect has been a longstanding question. A meta-analysis published in Nature Communications finds that placebo treatments to reduce pain, known as placebo analgesia, reduce pain-related activity in multiple areas of the brain.

If they can improve this, what else could they improve?

Despite these challenging times, challenging in so many more ways than we could've ever imagined, the new year brought some hope related to one part of our broken healthcare system, and it was a change that we never even really saw coming.

Although there's so much more to go, so many things that need fixing, many of us were surprised by the new CMS 2021 guidelines about Medicare billing and compliance. Who would've thought?

Even during the COVID-19 pandemic, opioid misuse has continued unabated in the United States, with an estimated 2.5 million or more Americans suffering from opioid use disorder. Most people treated for the disorder are given medications, such as buprenorphine, that activate opioid receptors. But there is disagreement about whether it's safe to prescribe buprenorphine for people who also take benzodiazepines, which are potentially addictive medications prescribed for stress, sleep, and anxiety.

New research involving the medical data of more than 23,000 patients being treated for opioid use disorder supports the use of buprenorphine in patients also taking benzodiazepines. Researchers at Washington University School of Medicine in St. Louis found that the drug can protect opioid users from overdosing, even when such patients also take benzodiazepines, such as Valium, Xanax, and Ativan.

Join the 2021 Annual Meeting in New Orleans, June 24-26, for the FIRST LIVE, MUST-ATTEND Meeting since COVID Shutdowns
The 23rd annual meeting will be educational (providing much needed CME credits), exciting, and will offer the long-awaited ability to leave our homes and attend meetings in a safe and responsible manner.

ASIPP is working to make the program highly relevant for our changing healthcare system and environment. We will also bring you cutting-edge lectures on exciting new technology, world-renowned speakers, and much, much more. Registration is now open. Topics will include: COVID-19, economics, burnout, social media, metabolic health, regulatory issues, scientific advances in IPM, and much more! 

Mark your calendars, book your room and click here to register!
Pain Medicine Case Reports (PMCR) and Editor-in-Chief Alaa Abd-Elsayed, MD, PhD would like to invite you to submit case reports and case series to PMCR journal. Your article will be published free of charge.

Open access journals are freely available online for immediate worldwide open access to the full text of published articles. There is no subscription fee for open access journals. Open access journals are no different from traditional subscription-based journals: they undergo the same peer-review and quality control as any other scholarly journal.

Interested in becoming a member of the PMCR Editorial Board?
Editorial board members are asked to review 2-6 manuscripts per year. Please submit your most up-to-date CV to sgold@asipp.org for consideration.

For more information or to submit your articles, click here.

Abstract
Background: Minimally invasive SI joint fusion has increased in popularity. A possible complication that can result from the procedure is a radiculopathy (sacral or lumbar) that is caused by placement of the SI joint fusion implant.

Case Report: Two cases are presented: A 60-year-old woman with a S1 radiculopathy secondary to a cortical bone fragment contacting the S1 nerve, and a 62-year-old man with a L5 radiculopathy and the anteriorly directed SI joint fusion implant positioned anteriorly and compressing on the L5 nerve. Both patients had resolution of their symptoms with endoscopic treatment.

ASIPP® is pleased to announce the publication of the Comprehensive Evidence-Based Guidelines for Epidural Interventions in the Management of Chronic Spinal Pain. In preparation for the guidelines, an extensive literature review was performed. The 210-page guidelines contain 33 figures, 48 tables, 1,345 references, and 60 authors.

In addition to the review of multiple manuscripts in reference to utilization, expenditures, anatomical and pathophysiological considerations, pharmacological and harmful effects of drugs and procedures, for evidence synthesis, we have included 47 systematic reviews and 43 RCTs covering all epidural. 

Abstract
Background: Persistent headaches and migraines are common in pediatrics with various treatment options. The sphenopalatine ganglion (SPG) has been identified as communicating with the parasympathetic autonomic nervous system and pain receptors. In adults, SPG block is an established treatment but there is no published literature in pediatrics.

Objectives: The purpose of this study is to analyze the SPG block in pediatrics.

Abstract
Background: Psychological comorbidities in chronic pain (CP) are common and contribute to adverse health outcomes and poor quality of life. Evidence-based guidance for the management of depressive symptoms in CP is limited, particularly for mind-body interventions.

Objectives: To investigate the effectiveness of mind-body interventions for the management of depressive symptoms in people with CP.

Its unique characteristics pose problems as well as opportunities

Now that Johnson & Johnson has joined Pfizer and Moderna in having a COVID-19 vaccine authorized in the U.S., the question on many people's minds is: who gets which vaccine?

Much of the discussion has focused on the differing vaccine efficacy numbers for the three products: those given for the J&J vaccine are in the 70% range, versus more than 90% for Pfizer's and Moderna's.

President Joe Biden's HHS continues to hire leaders to guide the department amid the COVID-19 pandemic.


A COVID relief bill backed by Democrats could trigger billions of dollars in cuts to Medicare and other federal programs, like ones that support unemployed workers and student-loan borrowers if it's ultimately passed.

The funding cuts would take effect in 2022 and last for several years.
After reading the 2021 Abstracts & Poster Presentations guidelines, please complete the form along with the presenter's CV by clicking here. Questions can be directed to Savannah Gold at 270-554-9412 x 4219 or sgold@asipp.org.

  • Selected manuscripts will be presented in electronic poster presentation.
  • Top 25 will be published in the Pain Physician journal. 
  • Top 10 will be selected for abstract presentation at meeting.
  • Top 3 will receive cash prizes.

A $50 submission fee is required, and will be collected at the end of this form.

Proposals will be accepted until April 14, 2021

Click here for Abstract and Poster Presentation Submission Guidelines
Election Results for ASIPP Board of Directors
Serving from April 2021 through March 2022
The election results are as follows:  

First Executive Vice-President: Salahadin Abdi, MD, PhD
 
Second Executive Vice-President: Christopher Gharibo, MD
 
Vice President-Strategic Affairs: Mahendra Sanapati, MD
 
Secretary: Annu Navani, MD

Treasurer: Devi Nampiaparampil, MD
 
Directors-at-Large: Deborah Tracy, MD | Ricardo Buenaventura, MD | Steve Aydin, DO 
 
Academic Directors: Kenneth Candido, MD | Joshua Hirsch, MD | Vanila Singh, MD
 
Young Physician Directors: Helen Blake, MD | Kunj Patel, MD | Kartic Rajput, MD
 
Resident/Fellow Board Member: Allan Parr, III
 
Directors Emeritus: Peter Staats, MD | Sudhir Diwan, MD
 
ASIPP will also recognize and introduce the new board during the 23rd Annual Meeting, June 24-26, in New Orleans. We hope you will join us for the meeting to congratulate the new board and to participate in and enjoy our long-awaited live meeting! 
Like and follow ASIPP on Facebook, Twitter and LinkedIn for the most
up-to-date news related to you, your practice, and patients!

Since this malpractice insurance program officially launched in November 2018, ASIPP has sign up hundreds of providers with an average savings of 30%. This is a professional liability insurance that is tailored to our specialty and will stand up for us and defend our practices.

Norcal Mutual is 'A' Rated by AM best and is license in all 50 states. To read a few important points to keep in mind about the program, including discounts, administrative defense, cyber coverage, aggressive claims handling, and complimentary award-winning risk management CME activities, click here.
Since this malpractice insurance program officially launched in November 2018, ASIPP has sign up hundreds of providers with an average savings of 30%. This is a professional liability insurance that is tailored to our specialty and will stand up for us and defend our practices.

Norcal Mutual is 'A' Rated by AM best and is license in all 50 states. To read a few important points to keep in mind about the program, including discounts, administrative defense, cyber coverage, aggressive claims handling, and complimentary award-winning risk management CME activities, click here.

ASIPP has formed a partnership with Henry Schein and PedsPal,
a national GPO that has a successful history of negotiating better prices on medical supplies and creating value added services for the independent physician. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today.

All sessions from the September 2020 meeting are available through June 2021 for a reduced fee. On-demand registration also provides access to all of the great resources available in the exhibit hall.

*Recorded sessions are not eligible for CME credits.


ASIPP is now offering our members the benefit of a unique revenue cycle management/billing service. We have received a tremendous amount of interest in the ASIPP billing and coding program. Click here to learn more about the negotiated rate for practices and more!